SCHEMBL2147223

SCHEMBL2147223

Cn1nccc1-c1c(C=NO)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
GAA P10253 2/20 0.38
ESR2 Q92731 4/20 0.37
ESR1 P03372 3/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KCNH2 Q12809 1/20 0.33
POLB P06746 1/20 0.32
KLK7 P49862 1/20 0.32
TSHR P16473 1/20 0.32
S1PR4 O95977 1/20 0.31
S1PR1 P21453 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2147220 1.00 LMNA (0.38) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146820 0.84 LMNA (0.35) LMNAGAAKDM4EMAPTNPC1
SCHEMBL2146817 0.84 LMNA (0.35) LMNAGAAKDM4EMAPTNPC1
SCHEMBL2146628 0.81 ESR2 (0.41) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146632 0.81 ESR2 (0.41) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146484 0.79 MAPT (0.34) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146478 0.79 MAPT (0.34) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146435 0.78 MAPT (0.46) LMNAGAAESR2ESR1KDM4E
SCHEMBL2146432 0.78 MAPT (0.46) LMNAGAAESR2ESR1KDM4E
SCHEMBL1076456 0.77 CYP11B2 (0.42) LMNAGAAESR2ESR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216268-A Novel estrogen receptor ligands KAROBIO AB 2011-10-12 CN claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 LMNA 3473/4885GAA 4152/4885ESR2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.